This next-generation bivalent COVID-19 vaccine candidate, BNT162b5, consists of RNAs encoding enhanced prefusion spike proteins for the SARS-CoV-2 ancestral strain (wild-type) and an Omicron variant.
Tealium for Pharma utilizes deep integration technology and partnerships to deliver an enhanced customer journey in one of healthcare's most vital sectors
The company has reported total income of Rs. 94.30 crores during the period ended June 30, 2022.
The Award reinforces Cadila’s digital initiatives which is backed by innovation, research & development and robust frameworks.
The region's digital health market, valued at USD 40.3 billion in 2021, is expected to expand to USD 326.7 billion by 2030 at a CAGR of 26.5 per cent.
Sun Pharma will receive from Cassiopea the exclusive right to develop and commercialize WINLEVI in Japan, Australia, New Zealand, Brazil, Mexico and Russia.
WuXi STA opens a new large scale continuous manufacturing plant
Better serving global partners and advancing healthcare innovation
Subscribe To Our Newsletter & Stay Updated
